Search Results for "edoxaban"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for edoxaban. Results 1 to 10 of 12 total matches.
See also: Savaysa
Edoxaban (Savaysa) - The Fourth New Oral Anticoagulant
The Medical Letter on Drugs and Therapeutics • Mar 30, 2015 (Issue 1465)
Edoxaban (Savaysa) - The Fourth New Oral Anticoagulant ...
The FDA has approved edoxaban (Savaysa – Daiichi
Sankyo), a once-daily, oral, direct factor Xa inhibitor,
for treatment of venous thromoboembolism (VTE)
and for prevention of stroke and systemic embolism
in patients with nonvalvular atrial fibrillation. It is the
fourth new oral anticoagulant to be approved for VTE
and nonvalvular atrial fibrillation.
New Oral Anticoagulants for Acute Venous Thromboembolism
The Medical Letter on Drugs and Therapeutics • Jan 06, 2014 (Issue 1433)
etexilate (Pradaxa), apixaban
(Eliquis), and edoxaban (not FDA-approved) have
all been studied ...
Anticoagulants are the drugs of choice for treatment
of deep vein thrombosis (DVT) and pulmonary
embolism (PE), collectively referred to as venous
thromboembolism (VTE).
Andexxa - An Antidote for Apixaban and Rivaroxaban
The Medical Letter on Drugs and Therapeutics • Jun 18, 2018 (Issue 1549)
inhibitors edoxaban (Savaysa)2 or
betrixaban (Bevyxxa).3
Pronunciation Key
Andexanet alfa: an dex' a net ...
Coagulation factor Xa (recombinant), inactivated-zhzo
(andexanet alfa; Andexxa – Portola) has received
accelerated approval from the FDA for urgent reversal
of the anticoagulant effect of the direct factor Xa
inhibitors apixaban (Eliquis) and rivaroxaban (Xarelto).
Andexanet alfa is the second antidote for a direct oral
anticoagulant to become available in the US, and the
fi rst for factor Xa inhibitors. Idarucizumab (Praxbind)
was approved in 2015 for reversal of the anticoagulant
effect of the direct thrombin inhibitor dabigatran
etexilate (Pradaxa). Andexanet alfa has not...
Which Oral Anticoagulant for Atrial Fibrillation?
The Medical Letter on Drugs and Therapeutics • Apr 11, 2016 (Issue 1492)
(Eliquis),
edoxaban (Savaysa), and rivaroxaban (Xarelto) do not
require routine monitoring of coagulation ...
Direct-to-consumer advertisements continue to
urge patients who take warfarin (Coumadin, and
others) for atrial fibrillation to ask their doctors
about the benefits of one or another of the newer
oral anticoagulants.
Idarucizumab (Praxbind) - An Antidote for Dabigatran
The Medical Letter on Drugs and Therapeutics • Nov 23, 2015 (Issue 1482)
the anticoagulant effects of the factor Xa
inhibitors apixaban (Eliquis), edoxaban (Savaysa), and
rivaroxaban ...
The FDA has approved idarucizumab (Praxbind –
Boehringer Ingelheim) for urgent reversal of the
anticoagulant effect of the direct thrombin inhibitor
dabigatran etexilate (Pradaxa). Idarucizumab is the
first specific reversal agent to become available for
one of the new oral anticoagulants.
Comparison Table: Some Oral Anticoagulants for VTE (online only)
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022 (Issue 1655)
mL/min.
Does not require INR monitoring
A DOAC (apixaban, edoxaban, dabigatran, rivaroxaban ...
View the Comparison Table: Some Oral Anticoagulants for VTE
Drugs for Treatment and Prevention of Venous Thromboembolism
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022 (Issue 1655)
therapy should be continued
for at least 3 months.3 A DOAC (apixaban, dabigatran
[Pradaxa], edoxaban ...
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). US guidelines for
treatment of VTE were updated in 2020 and 2021.
Antithrombotic Drugs
The Medical Letter on Drugs and Therapeutics • Oct 27, 2014 (Issue 1454)
with
apixaban (0.6% vs. 1.8%).41
EDOXABAN — A fourth factor Xa inhibitor, edoxaban
(Savaysa), may soon ...
Antiplatelet drugs are the drugs of choice for
prevention and treatment of arterial thrombosis.
Anticoagulants are the drugs of choice for prevention
and treatment of venous thromboembolism and for
prevention of cardioembolic events in patients with
atrial fibrillation.
Treatment of Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • Jan 08, 2024 (Issue 1693)
(Eliquis),
and edoxaban (Savaysa) are recommended over the
oral vitamin K antagonist warfarin ...
Atrial fibrillation (AF) is the most common arrhythmia
in the world. Risk factor modification, anticoagulation,
rhythm control, and rate control are the four pillars
of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines
on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8 doi:10.58347/tml.2024.1693a | Show Introduction Hide Introduction
Anticoagulation of Elderly Patients at High Risk for Falls with Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • Feb 27, 2017 (Issue 1515)
anticoagulants dabigatran etexilate (Pradaxa), rivaroxaban
(Xarelto), apixaban (Eliquis), and edoxaban
(Savaysa ...
With the widespread adoption of the CHA2DS2-VASc
scoring system, oral anticoagulation therapy is
now recommended for all patients ≥75 years old
with nonvalvular atrial fibrillation. Atrial fibrillation
has, however, been associated with an increased
risk of falls, and older patients starting warfarin for
atrial fibrillation have a high rate of hospitalization
for intracranial bleeding. Many practitioners are
reluctant, therefore, to prescribe an oral anticoagulant
for elderly patients who are at high risk for falls.